What TNF antagonist is known to bind both TNFα and TNFβ?

Etanercept is a unique TNF antagonist because it functions as a fusion protein that includes the extracellular portion of the TNF receptor. What sets etanercept apart from the other TNF antagonists is its ability to bind both forms of tumor necrosis factor: TNFα and TNFβ. This dual binding can effectively neutralize the actions of both types of TNF, which are involved in inflammatory processes.

In contrast, adalimumab (a monoclonal antibody) and infliximab (another monoclonal antibody) primarily target TNFα specifically and are not designed to interact with TNFβ. Certolizumab, while also a monoclonal antibody, has a similar specificity to adalimumab and infliximab in that it primarily targets TNFα. The broader range of action provided by etanercept may contribute to its effectiveness in treating conditions characterized by excessive TNF signaling, making it a valuable therapeutic option in certain inflammatory diseases.